Blood Test Reveals How Lung Cancer Outsmarts Osimertinib in Landmark Liquid Biopsy Study

When a targeted cancer drug stops working, the tumor usually leaves fingerprints — and a new study from Thailand shows those fingerprints can be lifted from a simple tube of blood. Researchers at Ramathibodi Hospital, Mahidol University, have used non-invasive molecular testing, often called liquid biopsy, to map how advanced non-small cell lung cancer (NSCLC) evades osimertinib, one of the most widely prescribed targeted therapies in the world. The findings, published in BMC Cancer, offer one of the most detailed real-world portraits yet of acquired resistance in Asian patients with EGFR T790M-positive disease, a population that has historically been underrepresented in resistance research.

Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI), engineered to block the epidermal growth factor receptor even when it carries the T790M mutation — the classic escape route tumors use to shrug off first- and second-generation TKIs like gefitinib and erlotinib. In the clinic, osimertinib transformed outcomes for these patients, but resistance is inevitable. Tumors eventually find new molecular workarounds, and knowing which workaround is operating in a given patient can determine the next treatment decision. The problem has always been access: getting that information traditionally requires a tissue biopsy, an invasive procedure that is often impractical in patients who are frail or whose tumors sit in hard-to-reach locations.

The Thai team, led by Piyakarn Watcharenwong and Narumol Trachu, who contributed equally to the work, set out to answer whether blood-based testing could capture the same resistance intelligence. Between January 2016 and December 2019, they prospectively enrolled patients with advanced EGFR T790M-positive NSCLC at Ramathibodi Hospital. Every participant had progressed on a first- or second-generation EGFR TKI before starting osimertinib. The researchers drew paired plasma samples — one before osimertinib treatment began and a second at the moment of disease progression — and analyzed the cell-free DNA (cfDNA) circulating in the blood using a targeted next-generation sequencing panel covering 52 cancer-relevant genes.

The technical logic behind this approach is elegant. Dying tumor cells shed fragments of their DNA into the bloodstream, and those fragments carry the same mutations driving the cancer. Sequencing cfDNA therefore offers a molecular snapshot of the tumor without a needle in the tumor itself. The 52-gene panel used in this study was broad enough to catch not just EGFR mutations but also alterations in other canonical resistance genes, including TP53, PIK3CA, BRAF, and amplification of MET, a receptor tyrosine kinase gene that tumors frequently overproduce to bypass EGFR blockade entirely.

Fifty patients had usable paired plasma samples, and what the sequencing revealed was strikingly heterogeneous. Nineteen patients — 38 percent of the cohort — carried more than one resistance-associated alteration at progression, confirming that resistance rarely arrives through a single door. At baseline, plasma T790M was detectable in 32 patients. By the time osimertinib failed, 16 of those 32 — exactly half, representing 32 percent of the overall cohort — had lost detectable T790M altogether. This loss matters clinically: T790M-negative tumors generally do not respond to earlier-generation TKIs, so a patient whose T790M vanishes has lost one of the few re-treatment options available to them.

The genomic alterations detected at progression painted a detailed resistance map. TP53 mutations appeared in 22 percent of patients, PIK3CA mutations in 14 percent, the EGFR C797S mutation — a direct on-target escape that alters the very amino acid osimertinib binds to — in 10 percent, BRAF mutations in 8 percent, and MET amplification in 2 percent. Each of these represents a distinct evolutionary strategy: C797S changes the drug’s binding pocket, MET amplification floods the cell with an alternative growth pathway, and PIK3CA and BRAF mutations activate downstream signaling cascades that no longer depend on EGFR at all.

Clinically, the cohort fared as expected for this stage of disease: median time to treatment failure (TTF) on osimertinib was 9.3 months and median overall survival (OS) was 16.4 months. But the molecular subgroups told a more nuanced story. Patients whose plasma T790M disappeared at progression had a numerically shorter TTF — 6.0 months versus 10.1 months for those who retained T790M — though the difference did not reach statistical significance (P = 0.21). Among patients with T790M loss, those who also carried co-occurring resistance alterations fared even worse, with a median TTF of 4.1 months compared with 10.6 months for those without co-alterations (P = 0.06), a trend that hovered just at the edge of significance in this small cohort.

Perhaps the most intriguing findings were the associations between specific resistance mechanisms and patterns of metastatic spread. In univariable analyses, the presence of brain metastasis at baseline was significantly associated with subsequent plasma T790M loss (P = 0.04). Metastasis to uncommon sites — locations outside the typical lung, bone, liver, and adrenal distribution — was significantly linked to the emergence of EGFR C797S (P < 0.01). And progression specifically in the brain during osimertinib treatment was significantly associated with BRAF mutations (P = 0.01). These correlations suggest that the anatomical environment a tumor spreads to may exert selective pressure shaping which resistance mechanism evolves, a hypothesis that could eventually guide which molecular tests clinicians order based on a patient’s metastatic pattern.

The study’s authors are careful to frame these as exploratory findings that require validation in larger cohorts with tissue-based analyses, and that caution is warranted. With fifty patients, the statistical power to detect modest differences is limited, and plasma-based cfDNA testing has known blind spots — alterations present at low allele fractions, or in tumor regions that shed little DNA, can go undetected. Brain metastases in particular are notoriously underrepresented in plasma cfDNA because the blood-brain barrier limits the exchange of circulating nucleic acids, which means some of the brain-associated findings may reflect biology that plasma testing only partially captures.

Even so, the study delivers a practical message with real clinical weight: a blood draw, repeated at the moment of progression, can reveal the molecular landscape of resistance in T790M-positive NSCLC and flag patients on faster trajectories of decline. As osimertinib continues to move into earlier lines of treatment worldwide, understanding — and monitoring — the mechanisms by which tumors escape it becomes ever more urgent. This Thai prospective cohort adds a valuable piece to that puzzle, demonstrating that liquid biopsy is not merely a convenience but a window into the evolutionary battle between drug and cancer, fought in real time and readable from a vial of blood.

Subject of Research: Liquid biopsy detection of acquired resistance mechanisms to osimertinib in EGFR T790M-positive advanced non-small cell lung cancer

Article Title: Non-invasive molecular testing of osimertinib acquired resistance in T790M-positive advanced non-small cell lung cancer

Article References: Watcharenwong, P., Trachu, N., Iemwimangsa, N., Munthum, D., Monnamo, N., Jiaranai, P., Charoenyingwattana, A., Nitiwarangkul, C., Chamroonrat, W., Chansriwong, P., Ativitavas, T., Dejthevaporn, T., Chantratita, W., & Reungwetwattana, T. (2026). Non-invasive molecular testing of osimertinib acquired resistance in T790M-positive advanced non-small cell lung cancer. BMC Cancer. https://doi.org/10.1186/s12885-026-17148-y

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17148-y

Keywords: osimertinib, EGFR T790M, non-small cell lung cancer, liquid biopsy, cell-free DNA, acquired resistance, next-generation sequencing, EGFR C797S, MET amplification, BRAF mutation, brain metastasis, targeted therapy